v3.26.3
Subsequent Events
9 Months Ended
Sep. 30, 2026
Subsequent Events [Abstract]  
Subsequent Events

Note 11. Subsequent Events

 

The Company has evaluated all subsequent events and transactions through November 9, 2026, the date that the consolidated financial statements were available to be issued and noted no subsequent events requiring financial statement recognition or disclosure other than what is identified below:

 

On June 21, 2025, the Company, Zoar Limited (formerly known as Dr Ashleys Limited), a Cayman Islands exempted company limited by shares (“Zoar” or “PubCo”), Dr Ashleys Nevada Sub, Inc., a Nevada corporation and wholly-owned subsidiary of PubCo (“Merger Sub”), Zoar Labs Limited (formerly known as Dr Ashleys Bio Labs Limited), a Cayman Islands exempted company limited by shares (“Zoar Labs”), and Kanans Visvanats (a.k.a. Kannan Vishwanatth), solely in his capacity as the sole shareholder of Zoar Labs (the “Zoar Labs Shareholder”), entered into a Merger and Share Exchange Agreement (as subsequently amended, the “Merger Agreement”). Pursuant to the Merger Agreement, and subject to its terms and conditions, (i) Merger Sub will merge with and into Impact, with Impact continuing as the surviving entity (the “Merger”), and (ii) simultaneously with or immediately following the Merger, PubCo will acquire all issued and outstanding ordinary shares of Zoar Labs from the Zoar Labs Shareholder (the “Share Exchange”). On October 23, 2026, the U.S. Securities and Exchange Commission (“SEC”) declared effective PubCo’s Registration Statement on Form F-4 relating to the proposed business combination. The transaction remains subject to certain closing conditions, including required stockholder and regulatory approvals and approval for listing PubCo’s ordinary shares on the NYSE American. The parties currently anticipate completing the transaction during the fourth quarter of 2026, subject to satisfaction or waiver of the remaining closing conditions. There can be no assurance that the transaction will be completed within the anticipated timeframe.

 

On October 7,2026, the Company granted and issued 45,870 shares of Common Stock to various individuals including executives, board members, audit committee members, The grant is valued at approximately $205,000.